Preparation method of externally-applied nursing articles for treating graves disease in pregnancy

Abstract

The invention discloses a preparation method of externally-applied nursing articles for treating a graves disease in pregnancy so as to solve the problem of treatment of the graves disease in pregnancy. The preparation method comprises the following steps: (1) mixing allium victorialis, magnolia amoena, lotus leaf, bark of himalayan coralbean, and essential oil extracted from fructus cannabis crude powder for later use, and remaining herb residues in employment; (2) mixing crab grass, sensitive joint vetch wood, vandenboschia auriculata, red clover flower and inflorescence, ardisiae japonica, loofah sponge, coked rice sprout and ferrosic oxide evenly, adding 5fold water and soaking for 6 hours, decocting, and adding ethanol to decoction, carrying out heat preservation at 60 DEG C, standing for 15 minutes, centrifuging, taking supernate and carrying out spray drying, so as to obtain a primary material; and (3) spraying the essential oil obtained from the step 1 into the primary material obtained from the step 2, filtering by a 100mesh sieve, and sub-packaging.

Description

Technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a preparation method of an external nursing product for treating hyperthyroidism of pregnancy. Background technique [0002] The incidence of pregnancy complicating hyperthyroidism (PCH) is about 0.1% to 0.4%. Among the endocrine diseases in pregnant women, thyroid disease is second only to diabetes, ranking second. PCH is a high-risk disease of pregnancy with great harm. The pregnancy miscarriage rate is as high as 26%, the premature delivery rate is 15%, and it is also prone to fetal growth restriction (FGR). The most important impact on the mother is the thyroid crisis. Once it occurs, the mortality rate can be as high as 25%, so it is very important to give timely and appropriate treatment to PCH patients during pregnancy. [0003] The vast majority of PCH is Grave disease, which accounts for more than 85% of all hyperthyroid patients. The exact pathogenesis is unknown. ...

AI Technical Summary

Problems solved by technology

At the same time, because the existing ATD can pass through the placental barrier, there are hidden dangers to the growth and development of the fetus. For example, excessive ATD will cause fetal hypothyroidism and goiter, which will affect the normal development of the fetus. Therefore, the existing clinical treatment plans mostly advocate pregnancy. The minimum dose of ATD should be applied in the long term, and the FT4 should not exceed 1.4 times the upper limit of normal

Due to the inability to use therapeutic drugs in sufficient quantities, FT4 remains at a high level, so the maternal and infant complications (such as miscarriage, premature delivery, fetal growth retardation, pregnancy-induced hypertension syndrome, etc.) of ATD treatment at this safe dose are not ideally controlled, and breastfeeding The recurrence rate in the early period is as high as 50% to 60%, which affects postpartum breastfeeding.

In addition, if the mother's hyperthyroidism has not been properly treated, neonatal hyperthyroidism will occur in 1 to 3% of the cases, and the mortality rate may reach 10% to 15%.

[0005] In addition, since β-adrenergic blockers can increase uterine muscle tone, resulting in placental dysplasia and fetal intrauterine growth retardation, it should not be used as the drug of choice in hyperthyroidism during pregnancy

For the control of tachycardia associated with PCH, there is currently no better drug